| Sažetak | Cilj istraživanja: Cilj ovog istraživanja bio je usporediti kvalitetu života u pacijenata na terapiji biološkim lijekom koji boluju od hidradenitis suppurativa ili boluju od teškog oblika psorijaze
Ispitanici i metode: U opažajnu, retrospektivnu studiju parova uključeno je ukupno 52 pacijenta na terapiji biološkim lijekom, 26 s dijagnozom hidradenitis suppurativa i 26 s dijagnozom teškog oblika psorijaze. Korištena je anketa i upitnici: Dermatološki indeks kvalitete života (DLQI), Beckov inventar depresije za žene i muškarce (BDI-II) i Upitnik o radnoj učinkovitosti i smetnjama u radu V2.0 (WPAI:GH). Uspoređen je rezultat DLQI između HS i psorijaze te između žena i muškaraca unutar skupina. Skupine su uspoređene s obzirom na broj promjenama zahvaćenih područja, dobi pri pojavi simptoma i postavljanju dijagnoze, prisutnost komorbiditeta, zadovoljstvo biološkom terapijom, kvalitetu života, prisutnost depresije, smetnje u radu i obavljanju svakodnevnih aktivnosti.
Rezultati: Rezultat DLQI u pacijenata s dijagnozom hidradenitis suppurativa (7,4 ± 5,8) značajno je lošiji u odnosu na pacijente s dijagnozom teškog oblika psorijaze (1,8 ± 2,5); P<0,001. U ispitivanju je utvrđena prisutnost statistički značajne razlike između spolova s lošijim rezultatom DLQI u muškaraca u obje skupine; P<0.05. Srednja vrijednost DLQI u muškaraca sa HS je 9,4 ± 5,7, u žena je 5,2 ± 5,1. U muškaraca sa psorijazom srednja vrijednost DLQI je 2,4 ± 3,1, a u žena 1,1 ± 1,6. DLQI rezultat u skupini pacijenata sa psorijazom je u značajnoj korelaciji s dobi pacijenata; P=0,045, dobi pri pojavi simptoma; P=0,016., ukupnim brojem komorbiditeta; P=0,032. U skupini pacijenata s dijagnozom HS utvrđena je statistički značajna povezanost između DLQI rezultata i zadovoljstva biološkom terapijom; P<0,001, prisutnosti depresije mjerene BDI-II rezultatom; P<0,001, utjecaja zdravstvenih problema na učinkovitost rada; P<0,001 i utjecaja zdravstvenih problema na obavljanje svakodnevnih aktivnosti; P<0,001.
Zaključci: Pacijenti koji boluju od hidradenitis suppurativa imaju značajno lošiju kvalitetu života od pacijenata koji boluju od teškog oblika psorijaze. Muškarci s dijagnozom HS ili psorijaze imaju narušeniju kvalitetu života od žena s dijagnozom HS ili psorijaze. |
| Sažetak (engleski) | Objectives: The aim of the present study was to compare quality of life among patients treated with a biologic drug who suffer from hidradenitis suppurativa or suffer from a severe form of psoriasis.
Subjects and methods: A total of 52 patients treated with biological drug, 26 with diagnosis of hidradenitis suppurativa and 26 with diagnosis of a severe form of psoriasis were included in the observational, retrospective study of couples. A survey and questionnaires: Dermatology Quality of Life Index (DLQI), Beck's Depression Inventory for women and men (BDI-II) and Work Productivity and Acitivity Impairment Questionnaire V2.0 (WPAI:GH) were used. DLQI results were compared between HS and psoriasis and between women and men within the groups. The groups were compared with regard to the number of affected skin areas, age at onset of symptoms and official diagnosis, presence of comorbidities, satisfaction with biological therapy, quality of life, presence of depression, interference with work and performing daily activities.
Results: The DLQI score among patients with hidradenitis suppurativa (7.4 ± 5.8) was significantly worse than DLQI score in the psoriasis group (1.8 ± 2.5); P<0.001. The difference was statistically significant between men and women, with men having higher scores; P<0.05. The mean DLQI score for men with HS was 9.4 ± 5.7, for women was 5.2 ± 5.1. In the psoriasis group, the mean DLQI score for men was 2.4 ± 3.1, for women was 1.1 ± 1.6. The DLQI score in the group of patients with psoriasis correlated with the age of the patients; P=0.045, age at onset of symptoms; P=0.016 and total number of comorbidities; P=0.032. In the group of patients with HS, a statistically significant association was found between DLQI score and satisfaction with biological therapy; P<0.001, presence of depression measured by BDI-II score; P<0.001, impact on the work productivity and performance of daily activities; P<0.001.
Conclusions: Patients with hidradenitis suppurativa have a significantly worse quality of life than patients suffering from a severe form of psoriasis. Men with diagnosis of HS or psoriasis have more impaired quality of life than women with HS or psoriasis. |
